Offering conducted to fund operations and general corporate purposes
By Devika Patel
Knoxville, Tenn., Aug. 3 - Rosetta Genomics Ltd. priced a $27.5 million public offering of stock with a $4.13 million greenshoe on Aug. 2, according to a 6-K filed Friday with the Securities and Exchange Commission. The offering was announced June 25.
The company will sell 5.5 million ordinary shares at $5.00 per share, which is a 29.68% discount to the Aug. 1 closing share price of $7.11.
Aegis Capital Corp. is the underwriter.
Settlement is expected Aug. 8.
Proceeds will be used for operations and other general corporate purposes.
Based in Rehovot, Israel, Rosetta Genomics develops and provides microRNA-based molecular diagnostics.
| Issuer: | Rosetta Genomics Ltd.
|
| Issue: | Ordinary shares
|
| Amount: | $27.5 million
|
| Greenshoe: | $4,125,000
|
| Shares: | 5.5 million
|
| Price: | $5.00
|
| Warrants: | No
|
| Underwriters: | Aegis Capital Corp.
|
| Announcement date: | June 25
|
| Pricing date: | Aug. 2
|
| Settlement date: | Aug. 8
|
| Stock symbol: | Nasdaq: ROSG
|
| Stock price: | $7.11 at close Aug. 1
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
